ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT
ALLHAT PARTICIPANT
ALLHAT POPULATION
ALLHAT TRIAL
ALLHAT TRIAL
ALPHA-1 ANTAGONIST
ANTIHYPERTENSIVE
ANTIHYPERTENSIVE AGENT
BPH
BPH
CORONARY HEART DISEASE
CHF
CHF
CHF
CHF
CHF
CHF
CHF
CHF
CELLULAR EFFECT
PHYSIOLOGIC STUDY CELLULAR EFFECT
CHRONIC VOLUME LOADING
CLINICAL TRIAL DATA
COMPARING DATA
COMPETING INTEREST
DIFFERENTIATION
DOXAZOSIN
ECFV
ELEVATED PLASMA
NOREPINEPHRINE LEVEL ELEVATED PLASMA
ENDOTHELIN-1
ENGLISH-LANGUAGE PAPER
EPIDEMIOLOGIC RESEARCH
EPIDEMIOLOGICAL
FLUID STATUS
PERIPHERAL ALPHA-1 ANTAGONIST FLUID STATUS
FRAMINGHAM HEART STUDY LOGISTIC REGRESSION COEFFICIENT
HEART ATTACK TRIAL
JNC VI
KAPLAN-MEIER CURVE
LIPID-LOWERING TREATMENT
LUND-JOHANSEN
MEDLINE
MEDLINE
MERCK/SER CLINICAL EPIDEMIOLOGY FELLOW
MILD HYPERTENSION STUDY
NJ
NATIONAL AMBULATORY MEDICAL CARE SURVEY
NATIONAL COMMITTEE
NEUROHORMONAL
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PHYSIOLOGIC STUDY
PROSTATISM EVIDENCE
PSATY
RELATIVE RISK
RELATIVE RISK
RELATIVE RISK
RAHWAY
SHEP PARTICIPANT
SHEP TRIAL
SHEP TRIAL
SHEP TRIAL
SUBJECT
VA COOPERATIVE STUDY
WITHDRAWAL
WYETH
ACTIVE-CONTROL TRIAL
ADDITION
ADRENERGIC ALPHA-ANTAGONIST
ALPHA BLOCKER
ALPHA-1
ALPHA-1 ANTAGONIST
CARDIAC RECEPTOR ALPHA-1
ALPHA-1 RECEPTOR INHIBITION
ANTIHYPERTENSIVE EFFECT
ANTIHYPERTENSIVE EFFICACY
ANTIHYPERTENSIVE THERAPY
ANTIHYPERTENSIVE
APOPTOSI
APOPTOSI
ASSESSED DIFFERENCE
ATENOLOL
ATENOLOL
BACKGROUND PHYSIOLOGIC LITERATURE
BASELINE
BASELINE
BETA BLOCKER
BETA RECEPTOR
BETA-BLOCKER
BIBLIOGRAPHIC SEARCH
BLOOD-PRESSURE REDUCTION
CAPTOPRIL
CAPTOPRIL
CARDIAC BETA RECEPTOR STIMULATION
CARDIAC DAMAGE
CARDIAC RECEPTOR
CARDIOTOXIC
CARDIOVASCULAR COMPLICATION
CARDIOVASCULAR DISEASE
CARDIOVASCULAR ENDPOINT
CARDIOVASCULAR ENDPOINT
CARDIOVASCULAR ENDPOINT
CARDIOVASCULAR ENDPOINT
CARDIOVASCULAR EVENT
CARDIOVASCULAR OUTCOME
CASE CONTROL
CATECHOLAMINE LEVEL
CELLULAR INJURY
CELLULAR REPAIR MECHANISM
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE
CHLORTHALIDONE ARM
CHLORTHALIDONE ARM
CHOLESTEROL
CHOLESTEROL LEVEL
CHRONIC CONGESTIVE HEART FAILURE
CHRONIC SODIUM HOMEOSTASI
CHRONIC THERAPY
CHRONIC THERAPY
CLINICAL HEART FAILURE
CLINICAL HEART FAILURE EVENT
CLINICAL PRESENTATION
HEART FAILURE CLINICAL PRESENTATION
CLINICAL TRIAL
CLONIDINE
CLONIDINE
COHORT
COMPARATIVE TRIAL
COMPARING ATENOLOL
CONCENTRATION
NOREPINEPHRINE CONCENTRATION
CONCOMITANT ALPHA-1 BLOCKADE
CONGESTIVE HEART FAILURE
CONTROLLED TRIAL
COMPARING ATENOLOL CONTROLLED TRIAL
CONTROLLED TRIAL
CONTROLLED TRIAL
DEMOGRAPHIC
DIASTOLIC BLOOD PRESSURE
DIASTOLIC HYPERTENSION
DILTIAZEM
DIURETIC
DIURETIC
DIURETIC
DIVERSE PATIENT POPULATION
DOSE DIURETIC
DOUBLE-BLIND
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN
DOXAZOSIN ARM
DOXAZOSIN ARM
ALLHAT DOXAZOSIN ARM
DOXAZOSIN ARM TERMINATION
DOXAZOSIN GAIN WEIGHT
DOXAZOSIN UNMASKING INCIPIENT HEART FAILURE
ENDOTHELIN-1
ERST
EXTRACELLULAR FLUID VOLUME
FIRST-LINE BLOOD PRESSURE AGENT
FLUID RETENTION
FRACTIONAL EXCRETION
SODIUM FRACTIONAL EXCRETION
HEART FAILURE
HEART FAILURE
HEART FAILURE
HEART FAILURE
HEART FAILURE
HEART FAILURE
HEART FAILURE FINDING
HEART FAILURE OCCURRENCE
HEAT SHOCK PROTEIN EXPRESSION
HISTOLOGIC EVIDENCE
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
HYPERTENSION THERAPY
HYPERTENSIVE MAN
HYPERTENSIVE PATIENT
HYPERTENSIVE PATIENT
INCREASED PLASMA
INJURY
INTENSIVE DIETARY COUNSELING
INTERPRETATION
INTERSTITIAL FLUID VOLUME
KEY WORD
KEY WORD
LABORATORY CHANGE
LIFE-PROLONGING THERAPY
LINE AGENT
PHARMACOLOGIC TREATMENT LINE AGENT
LIPID PROFILE
LOW-DOSE
LOW-DOSE CHLORTHALIDONE
LOW-DOSE CHLORTHALIDONE
CHLORTHALIDONE ARM LOW-DOSE
LOW-DOSE DIURETIC
LOW-DOSE DIURETIC
LOW-DOSE DIURETIC
LOWERING BLOOD PRESSURE
ML AVERAGE INCREASE
MMHG
MMHG DIFFERENCE
MMHG HIGHER
MYOCARDIAL DAMAGE
MYOCARDIAL INJURY
MYOCARDIUM
MYOCYTE
NEGATIVE EFFECT
NEUROHORMONAL CHANGE
NEUROHORMONAL LEVEL
NONFATAL HEART FAILURE EVENT
NOREPINEPHRINE
NOREPINEPHRINE
NOREPINEPHRINE
NOREPINEPHRINE
NOREPINEPHRINE LEVEL
NORMOTENSIVE PATIENT
ORIGINAL BASELINE WEIGHT
PARTICIPANT
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1 ANTAGONIST
LOWERING BLOOD PRESSURE PERIPHERAL ALPHA-1 ANTAGONIST
PERSON-YEAR
PERSON-YEAR
PERTURBATION
PHARMACOLOGIC TREATMENT
PHYSIOLOGY STUDY
PLASMA NOREPINEPHRINE
PLASMA VOLUME
PLASMA VOLUME
PLASMA VOLUME FLUID EXPANSION
POPULATION DIFFERENCE
POSITIVE ACTION
POSITIVE EFFECT
PERIPHERAL ALPHA-1 ANTAGONIST POSITIVE EFFECT
POTENTIAL ASSOCIATION
PRAZOSIN
PRAZOSIN
PRAZOSIN
PRAZOSIN
PRAZOSIN
PRAZOSIN
PRAZOSIN ARM
PRAZOSIN BLOCK
HEAT SHOCK PROTEIN EXPRESSION PRAZOSIN BLOCK
PRAZOSIN DECREASED
PRIMARY OUTCOME
CORONARY HEART DISEASE PRIMARY OUTCOME
PROSTATIC HYPERTROPHY
PROSTATISM
PROSTATISM
RADIOISOTOPIC ASSAY
RAMIFICATION
RANDOMIZED TRIAL
RAT MYOCYTE
RECOMMENDATION
REFERENCE POINT
HEART FAILURE REFERENCE POINT
RELATIVE RISK
RENAL EFFECT
PRAZOSIN RENAL EFFECT
REVEALED INCREASE
RISK REDUCTION
RISK REDUCTION
CLINICAL HEART FAILURE RISK REDUCTION
ROUTINE USE
PERIPHERAL ALPHA-1 ANTAGONIST ROUTINE USE
SECOND-LINE ANTI-HYPERTENSIVE THERAPY
SECONDARY OUTCOME
TOTAL MORTALITY SECONDARY OUTCOME
SECONDARY OUTCOME
SODIUM
STARTING POINT
STUDY POPULATION
SUBCLINICAL DISEASE
SUBCLINICAL VENTRICULAR DYSFUNCTION
SUGGESTING MECHANISM
SYMPTOMATIC EPISODE
SYMPTOM
SYSTOLIC BLOOD PRESSURE
SYSTOLIC BLOOD PRESSURE
SYSTOLIC BLOOD PRESSURE
TERAZOSIN
TERAZOSIN
TERAZOSIN
TERAZOSIN
TERMINATION RATE
TERMINATION RATE
TOLERABILITY
TOLERABILITY
TOLERABILITY TRIAL
TOTAL BODY SODIUM
TOTAL BODY SODIUM
TOTAL MORTALITY
TREATMENT GROUP
TRIAL ARM
TWO-WEEK WASHOUT PERIOD
VASCULAR HORMONE
VENTRICULAR FUNCTION
VOLUME EXPANSION
VOLUME EXPANSION
VOLUME EXPANSION
PRAZOSIN VOLUME EXPANSION
VON WILLEBRAND FACTOR
WEIGHT CHANGE
WEIGHT CHANGE
WEIGHT CHANGE
WEIGHT GAIN
WEIGHT GAIN
WEIGHT GAIN
WEIGHT INFORMATION
WEIGHT LOSS
WEIGHT LOSS
WITHDRAWAL
TREATMENT OF MILD HYPERTENSION           STUDY
TOMHS
populations
trials
trials
ANTIHYPERTENSIVE
CLINICAL TRIAL
EPIDEMIOLOGIC
RESEARCH
FRAMINGHAM HEART STUDY LOGISTIC REGRESSION
HEART
ATTACK TRIAL
VI
KAPLAN-MEIER
TREATMENT
HYPERTENSION STUDY
AMBULATORY MEDICAL CARE SURVEY
MEDICAL CARE SURVEY
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PHYSIOLOGIC
PROSTATISM
EVIDENCE
trials
trials
trials
COOPERATIVE STUDY
trials
ADRENERGIC
BLOCKER
receptor inhibition
receptors
therapies
PHYSIOLOGIC
reductions
BETA RECEPTOR STIMULATION
RECEPTOR STIMULATION
receptors
DAMAGE
cases
controls
INJURY
CELLULAR REPAIR
CONGESTIVE HEART FAILURE
HEART FAILURE
CHRONIC SODIUM
therapies
therapies
HEART FAILURE
CLINICAL HEART FAILURE
presentations
trials
ATENOLOL
ALPHA-1 BLOCKADE
HEART FAILURE
trials
blood pressure
DIVERSE PATIENT
DOXAZOSIN ARM
ARM TERMINATION
GAIN WEIGHT
UNMASKING INCIPIENT HEART FAILURE
INCIPIENT HEART FAILURE
FLUID VOLUME
BLOOD PRESSURE AGENT
PRESSURE AGENT
RETENTION
EXCRETION
HEART
FAILURE
HEART
FAILURE
HEART
FAILURE
HEART
FAILURE
HEART
FAILURE
HEART
FAILURE
HEART FAILURE
HEART
HEART FAILURE
HEART
SHOCK PROTEIN EXPRESSION
protein expression
EVIDENCE
therapies
HYPERTENSIVE
DIETARY COUNSELING
FLUID VOLUME
words
KEY
therapies
lines
CHLORTHALIDONE
CHLORTHALIDONE
blood pressure
AVERAGE INCREASE
differences
DAMAGE
INJURY
effects
NONFATAL HEART FAILURE
BASELINE WEIGHT
BASELINE
PERIPHERAL ALPHA-1
ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1
ALPHA-1 ANTAGONIST
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
PERIPHERAL ALPHA-1
TREATMENT
studies
NOREPINEPHRINE
VOLUME FLUID EXPANSION
FLUID EXPANSION
populations
associations
outcomes
hypertrophy
references
RISK
effects
RISK
reductions
RISK
reductions
uses
ANTI-HYPERTENSIVE THERAPY
outcomes
studies
ventricular dysfunction
blood pressure
blood pressure
blood pressure
TERMINATION
TERMINATION
MORTALITY
TREATMENT
trials
hormones
functions
expansions
expansions
expansions
WILLEBRAND FACTOR
weights
changes
weights
changes
weights
weights
gains
weights
gains
weights
gains
weights
INFORMATION
weights
losses
weights
losses
